nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—CYP2C9—Teniposide—lymphatic system cancer	0.064	0.35	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Cytarabine—lymphatic system cancer	0.0378	0.206	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Teniposide—lymphatic system cancer	0.0372	0.203	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Mitoxantrone—lymphatic system cancer	0.026	0.142	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vincristine—lymphatic system cancer	0.0179	0.0979	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Teniposide—lymphatic system cancer	0.0156	0.71	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vincristine—lymphatic system cancer	0.00638	0.29	CbGdCrCtD
Medroxyprogesterone Acetate—Erythema—Carmustine—lymphatic system cancer	0.00091	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Vincristine—lymphatic system cancer	0.000905	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Teniposide—lymphatic system cancer	0.000903	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000899	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Bleomycin—lymphatic system cancer	0.000887	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Bleomycin—lymphatic system cancer	0.000887	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Vincristine—lymphatic system cancer	0.000881	0.00111	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Carmustine—lymphatic system cancer	0.00088	0.00111	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Bleomycin—lymphatic system cancer	0.000876	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Vincristine—lymphatic system cancer	0.000874	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Mitoxantrone—lymphatic system cancer	0.000872	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000871	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Neoplasm—Methotrexate—lymphatic system cancer	0.000871	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Bladder pain—Methotrexate—lymphatic system cancer	0.000871	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Mitoxantrone—lymphatic system cancer	0.000858	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Bleomycin—lymphatic system cancer	0.000857	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000855	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Tremor—Carmustine—lymphatic system cancer	0.000852	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Bleomycin—lymphatic system cancer	0.00085	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00085	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Mitoxantrone—lymphatic system cancer	0.000846	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Bleomycin—lymphatic system cancer	0.000845	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Carmustine—lymphatic system cancer	0.000841	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Vincristine—lymphatic system cancer	0.00084	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Teniposide—lymphatic system cancer	0.000839	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Sepsis—Methotrexate—lymphatic system cancer	0.000836	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Carmustine—lymphatic system cancer	0.000836	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000833	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Fludarabine—lymphatic system cancer	0.000832	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Teniposide—lymphatic system cancer	0.000832	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Teniposide—lymphatic system cancer	0.000831	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000828	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Teniposide—lymphatic system cancer	0.000827	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Fludarabine—lymphatic system cancer	0.000821	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Mitoxantrone—lymphatic system cancer	0.000818	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Bleomycin—lymphatic system cancer	0.000811	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000808	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000804	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Vincristine—lymphatic system cancer	0.000803	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Vincristine—lymphatic system cancer	0.000798	0.001	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Bleomycin—lymphatic system cancer	0.000795	0.001	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000794	0.000998	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Carmustine—lymphatic system cancer	0.000788	0.000991	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000785	0.000987	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Teniposide—lymphatic system cancer	0.000784	0.000986	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000782	0.000983	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Vincristine—lymphatic system cancer	0.00078	0.000981	CcSEcCtD
Medroxyprogesterone Acetate—Hepatic failure—Methotrexate—lymphatic system cancer	0.000778	0.000979	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000775	0.000975	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Carmustine—lymphatic system cancer	0.000774	0.000974	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Carmustine—lymphatic system cancer	0.000774	0.000974	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Carmustine—lymphatic system cancer	0.000772	0.000971	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Bleomycin—lymphatic system cancer	0.000764	0.000961	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Mitoxantrone—lymphatic system cancer	0.000763	0.000959	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000758	0.000954	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Vincristine—lymphatic system cancer	0.000752	0.000946	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Carmustine—lymphatic system cancer	0.000748	0.000942	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Carmustine—lymphatic system cancer	0.000742	0.000934	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000739	0.00093	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Vincristine—lymphatic system cancer	0.000739	0.00093	CcSEcCtD
Medroxyprogesterone Acetate—Visual disturbance—Methotrexate—lymphatic system cancer	0.000738	0.000929	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Carmustine—lymphatic system cancer	0.000737	0.000928	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Fludarabine—lymphatic system cancer	0.000737	0.000928	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Mitoxantrone—lymphatic system cancer	0.000733	0.000922	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Fludarabine—lymphatic system cancer	0.000731	0.00092	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Fludarabine—lymphatic system cancer	0.000731	0.000919	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000727	0.000914	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Fludarabine—lymphatic system cancer	0.000727	0.000914	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Carmustine—lymphatic system cancer	0.000724	0.000911	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000723	0.000909	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Mitoxantrone—lymphatic system cancer	0.00072	0.000906	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Mitoxantrone—lymphatic system cancer	0.00072	0.000906	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00072	0.000906	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Mitoxantrone—lymphatic system cancer	0.000717	0.000902	CcSEcCtD
Medroxyprogesterone Acetate—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000714	0.000898	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Mitoxantrone—lymphatic system cancer	0.000711	0.000895	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000709	0.000891	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Vincristine—lymphatic system cancer	0.000709	0.000891	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Carmustine—lymphatic system cancer	0.000708	0.00089	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Vincristine—lymphatic system cancer	0.000704	0.000886	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000701	0.000882	CcSEcCtD
Medroxyprogesterone Acetate—Osteoarthritis—Methotrexate—lymphatic system cancer	0.0007	0.00088	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Mitoxantrone—lymphatic system cancer	0.000696	0.000875	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Vincristine—lymphatic system cancer	0.000695	0.000874	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000694	0.000873	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Carmustine—lymphatic system cancer	0.000694	0.000873	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Mitoxantrone—lymphatic system cancer	0.00069	0.000868	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00069	0.000868	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Fludarabine—lymphatic system cancer	0.000689	0.000867	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Mitoxantrone—lymphatic system cancer	0.000686	0.000862	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000685	0.000862	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Mitoxantrone—lymphatic system cancer	0.000679	0.000854	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000676	0.000851	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000676	0.00085	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Bleomycin—lymphatic system cancer	0.000676	0.00085	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Vincristine—lymphatic system cancer	0.000675	0.00085	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000674	0.000847	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000672	0.000846	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Carmustine—lymphatic system cancer	0.000671	0.000845	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00067	0.000843	CcSEcCtD
Medroxyprogesterone Acetate—Irritability—Methotrexate—lymphatic system cancer	0.000668	0.00084	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000667	0.000839	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Carmustine—lymphatic system cancer	0.000667	0.000839	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Methotrexate—lymphatic system cancer	0.000663	0.000834	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Vincristine—lymphatic system cancer	0.000662	0.000833	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Carmustine—lymphatic system cancer	0.000662	0.000833	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Carmustine—lymphatic system cancer	0.00066	0.00083	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000658	0.000828	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Methotrexate—lymphatic system cancer	0.000658	0.000827	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000646	0.000812	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Carmustine—lymphatic system cancer	0.000645	0.000812	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Mitoxantrone—lymphatic system cancer	0.000645	0.000811	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Vincristine—lymphatic system cancer	0.000641	0.000806	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000641	0.000806	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Vincristine—lymphatic system cancer	0.000636	0.0008	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Carmustine—lymphatic system cancer	0.000635	0.000799	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Methotrexate—lymphatic system cancer	0.000632	0.000795	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000629	0.000791	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000627	0.000788	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00062	0.00078	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Vincristine—lymphatic system cancer	0.000616	0.000775	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000615	0.000774	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Mitoxantrone—lymphatic system cancer	0.000614	0.000772	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000612	0.00077	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Carmustine—lymphatic system cancer	0.000612	0.00077	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Vincristine—lymphatic system cancer	0.000611	0.000769	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Bleomycin—lymphatic system cancer	0.00061	0.000768	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000607	0.000764	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000607	0.000764	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Vincristine—lymphatic system cancer	0.000606	0.000762	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Methotrexate—lymphatic system cancer	0.000605	0.000761	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Bleomycin—lymphatic system cancer	0.000602	0.000757	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0006	0.000755	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000595	0.000748	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Mitoxantrone—lymphatic system cancer	0.00059	0.000742	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Carmustine—lymphatic system cancer	0.000587	0.000738	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Carmustine—lymphatic system cancer	0.000587	0.000738	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00058	0.000729	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000579	0.000729	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000569	0.000715	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Methotrexate—lymphatic system cancer	0.000565	0.000711	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000564	0.00071	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000562	0.000707	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Vincristine—lymphatic system cancer	0.00056	0.000705	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Vincristine—lymphatic system cancer	0.00056	0.000705	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Mitoxantrone—lymphatic system cancer	0.000548	0.00069	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Carmustine—lymphatic system cancer	0.000547	0.000688	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000546	0.000686	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000546	0.000686	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Bleomycin—lymphatic system cancer	0.000541	0.00068	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Methotrexate—lymphatic system cancer	0.000539	0.000678	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Methotrexate—lymphatic system cancer	0.000539	0.000678	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Methotrexate—lymphatic system cancer	0.000539	0.000678	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Methotrexate—lymphatic system cancer	0.000538	0.000676	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Bleomycin—lymphatic system cancer	0.000536	0.000675	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Bleomycin—lymphatic system cancer	0.000536	0.000674	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Carmustine—lymphatic system cancer	0.000533	0.00067	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Methotrexate—lymphatic system cancer	0.000525	0.000661	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Vincristine—lymphatic system cancer	0.000522	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Methotrexate—lymphatic system cancer	0.000517	0.00065	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00051	0.000641	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Methotrexate—lymphatic system cancer	0.000508	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000508	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Vincristine—lymphatic system cancer	0.000508	0.00064	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Carmustine—lymphatic system cancer	0.000508	0.000639	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Bleomycin—lymphatic system cancer	0.000505	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000495	0.000623	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Carmustine—lymphatic system cancer	0.000491	0.000618	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Methotrexate—lymphatic system cancer	0.000486	0.000612	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Vincristine—lymphatic system cancer	0.000485	0.00061	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Methotrexate—lymphatic system cancer	0.000484	0.000609	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Methotrexate—lymphatic system cancer	0.000484	0.000609	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Methotrexate—lymphatic system cancer	0.00048	0.000604	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000478	0.000601	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Methotrexate—lymphatic system cancer	0.000474	0.000597	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000472	0.000594	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Carmustine—lymphatic system cancer	0.000472	0.000594	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Vincristine—lymphatic system cancer	0.000469	0.000589	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Carmustine—lymphatic system cancer	0.000468	0.000589	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Carmustine—lymphatic system cancer	0.000468	0.000588	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Methotrexate—lymphatic system cancer	0.000466	0.000587	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Carmustine—lymphatic system cancer	0.000465	0.000585	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000458	0.000576	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—lymphatic system cancer	0.000452	0.000569	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—lymphatic system cancer	0.000451	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vincristine—lymphatic system cancer	0.000451	0.000567	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000449	0.000565	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vincristine—lymphatic system cancer	0.000447	0.000562	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vincristine—lymphatic system cancer	0.000446	0.000562	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vincristine—lymphatic system cancer	0.000444	0.000558	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Carmustine—lymphatic system cancer	0.000441	0.000555	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—lymphatic system cancer	0.000439	0.000552	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000439	0.000552	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000437	0.00055	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000436	0.000549	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Mitoxantrone—lymphatic system cancer	0.000435	0.000547	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000435	0.000547	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—lymphatic system cancer	0.000434	0.000546	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Mitoxantrone—lymphatic system cancer	0.000432	0.000544	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—lymphatic system cancer	0.000428	0.000538	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—lymphatic system cancer	0.000424	0.000533	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—lymphatic system cancer	0.000421	0.00053	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—lymphatic system cancer	0.000421	0.00053	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Vincristine—lymphatic system cancer	0.000421	0.000529	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000413	0.000519	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mitoxantrone—lymphatic system cancer	0.00041	0.000516	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—lymphatic system cancer	0.000408	0.000513	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000391	0.000492	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—lymphatic system cancer	0.000389	0.00049	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—lymphatic system cancer	0.00038	0.000478	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—lymphatic system cancer	0.000379	0.000476	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—lymphatic system cancer	0.000365	0.000459	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—lymphatic system cancer	0.000359	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—lymphatic system cancer	0.000359	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—lymphatic system cancer	0.000359	0.000451	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000356	0.000448	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—lymphatic system cancer	0.000354	0.000446	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—lymphatic system cancer	0.000347	0.000436	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000344	0.000433	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—lymphatic system cancer	0.000342	0.00043	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000337	0.000424	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000337	0.000423	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—lymphatic system cancer	0.000334	0.00042	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000332	0.000418	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—lymphatic system cancer	0.000328	0.000412	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—lymphatic system cancer	0.000321	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000313	0.000394	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—lymphatic system cancer	0.000311	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000309	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000307	0.000386	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—lymphatic system cancer	0.000306	0.000385	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000303	0.000381	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000299	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000297	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—lymphatic system cancer	0.000296	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000283	0.000356	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000281	0.000354	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—lymphatic system cancer	0.000273	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000272	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000272	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000253	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—lymphatic system cancer	0.000247	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—lymphatic system cancer	0.000243	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000235	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—lymphatic system cancer	0.000227	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—lymphatic system cancer	0.000219	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—lymphatic system cancer	0.000217	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—lymphatic system cancer	0.000217	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—lymphatic system cancer	0.000215	0.000271	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Methotrexate—lymphatic system cancer	0.000204	0.000257	CcSEcCtD
